Samuel Hume ✓

@DrSamuelBHume · joined 04 Jan 2019

Doctor, scientist | Trying to speed up science and solve disease

61 524Followers

1 604Following

4 439Posts total

216.2KViews on collected posts

โพสต์ล่าสุด

Samuel Hume ✓@DrSamuelBHume12 Sep

@DrSamuelBHume Short term great, long-term studies needed for cancer risky 2.8K views · 21 likes · 0 reposts · 2 replies Open on X →

Samuel Hume ✓@DrSamuelBHume12 Sep

Presented recently at the American Diabetes Association: https://t.co/s0oQIfkkOS 5.5K views · 32 likes · 2 reposts · 0 replies Open on X →

Samuel Hume ✓@DrSamuelBHume12 Sep

Cool pre-clinical weight loss drug from Korea. It hits 4 receptors: GLP1 - GIP - human growth hormone (hGH) - activin type II receptor (ActRII). It ~matches tirzepatide for weight loss, with more fat loss and less lean mass loss. 99.5% of weight loss was fat: https://t.co/pXXn

127.4K views · 1K likes · 90 reposts · 33 replies Open on X →

Samuel Hume ✓@DrSamuelBHume3 Sep

"GPT-6 Astra saturates the eval" 4.5K views · 16 likes · 1 reposts · 1 replies Open on X →

Samuel Hume ✓@DrSamuelBHume2 Sep

How do GLP1s affect the musculoskeletal system? Bone? Mixed evidence, probably no effect Joints? Protects cartilage, probable direct effect Tendon? Anecdotal evidence of snapping Muscle? It is adaptive, not maladaptive, muscle loss @peterkcrane, founder of EnteloBio, explains: 5.8K views · 42 likes · 6 reposts · 5 replies Open on X →

Samuel Hume ✓@DrSamuelBHume2 Sep

Old female mice, equivalent to 60 year old humans, taking the GLP1 receptor agonist, semaglutide: - Move more, with better balance and coordination (protection against frailty?) - Have better cognitive function (perform better on tests of learning and memory) - Have better http 40.9K views · 375 likes · 55 reposts · 10 replies Open on X →

Samuel Hume ✓@DrSamuelBHume1 Sep

The ongoing Ebola outbreak has grown faster than any previous outbreak — but it MIGHT now be slowing down. https://t.co/i4adKwIHHE 2.9K views · 15 likes · 1 reposts · 0 replies Open on X →

Samuel Hume ✓@DrSamuelBHume30 Aug

This week in medicine 1. Revolution Medicines' daraxonrasib gets FDA-approved! 2. Moderna's personalized cancer vaccine succeeds in a phase 3 trial for melanoma 3. Nektar's Treg-boosting antibody treats eczema in a phase 2 trial 4. Researchers at the Universities of 26.3K views · 334 likes · 52 reposts · 17 replies Open on X →

เทียบกับบัญชีขนาดเดียวกัน

8 โพสต์จาก 90 วันที่ผ่านมา เทียบกับช่วง 10K–100K ผู้ติดตาม แสดงในวงกว้าง แต่มีผู้ชมตอบสนองน้อย.

ยอดดูมัธยฐาน5 668บัญชีนี้924ค่ามัธยฐานของ 10K–100K

การเข้าถึง, %9.21%บัญชีนี้3.62%ค่ามัธยฐานของ 10K–100K

การมีส่วนร่วม, %0.86%บัญชีนี้1.52%ค่ามัธยฐานของ 10K–100K

ตัวชี้วัด	บัญชีนี้	ค่ามัธยฐานของ 10K–100K	อัตราส่วน
ยอดดูมัธยฐานต่อโพสต์	5 668	924	6.13×
การเข้าถึง (ยอดดู ÷ ผู้ติดตาม)	9.21%	3.62%	2.54×
อัตราการมีส่วนร่วม	0.86%	1.52%	0.56×

บัญชีอื่นในช่วงนี้ → เปรียบเทียบกับบัญชีอื่น → ค่าอ้างอิงเหล่านี้คำนวณอย่างไร →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

26.3K30 Aug

2.9K1 Sep

40.9K2 Sep

5.8K

4.5K3 Sep

127.4K12 Sep

5.5K

2.8K

Last 8 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

1.56%30 Aug

0.55%1 Sep

1.09%2 Sep

0.92%

0.40%3 Sep

0.90%12 Sep

0.61%

0.82%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes64.2%1 855 in total

Reposts7.2%207 in total

Replies2.4%68 in total

Quotes0.4%12 in total

Bookmarks25.9%747 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

โพสต์ล่าสุด

เทียบกับบัญชีขนาดเดียวกัน

Growth & engagement

Views per post

Engagement rate per post

What the audience does

บัญชีที่คล้ายกัน